Edgewise Therapeutics Stock Today
| EWTX Stock | USD 23.61 0.21 0.88% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Edgewise Therapeutics is trading at 23.61 as of the 21st of March 2025; that is 0.88 percent decrease since the beginning of the trading day. The stock's open price was 23.82. Edgewise Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 2021 | Category Healthcare | Classification Health Care |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Edgewise Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 95.21 M outstanding shares of which 8.06 M shares are currently shorted by private and institutional investors with about 8.97 trading days to cover. More on Edgewise Therapeutics
Moving against Edgewise Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Edgewise Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Kevin Koch | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEdgewise Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Edgewise Therapeutics' financial leverage. It provides some insight into what part of Edgewise Therapeutics' total assets is financed by creditors.
| |||||
Edgewise Therapeutics (EWTX) is traded on NASDAQ Exchange in USA. It is located in 1715 38th Street, Boulder, CO, United States, 80301 and employs 110 people. Edgewise Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.27 B. Edgewise Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 95.21 M outstanding shares of which 8.06 M shares are currently shorted by private and institutional investors with about 8.97 trading days to cover.
Edgewise Therapeutics currently holds about 248.4 M in cash with (109.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99.
Check Edgewise Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Edgewise Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Edgewise Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Edgewise Therapeutics. Please pay attention to any change in the institutional holdings of Edgewise Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Edgewise Ownership Details
Edgewise Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Deerfield Management Co | 2024-12-31 | 2.1 M | |
| State Street Corp | 2024-12-31 | 1.7 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.6 M | |
| Driehaus Capital Management Llc | 2024-12-31 | 1.5 M | |
| Bellevue Group Ag | 2024-12-31 | 1.4 M | |
| Viking Global Investors Lp | 2024-12-31 | 1.2 M | |
| Mpm Oncology Impact Management Lp | 2024-12-31 | 1.1 M | |
| Artisan Partners Limited Partnership | 2024-12-31 | 1.1 M | |
| New Leaf Venture Partners, L.l.c. | 2024-12-31 | 1 M | |
| Orbimed Advisors, Llc | 2024-12-31 | 15 M | |
| Ra Capital Management, Llc | 2024-12-31 | 8.9 M |
Edgewise Therapeutics Historical Income Statement
Edgewise Stock Against Markets
Edgewise Therapeutics Corporate Management
| Badreddin Edris | CoFounder Director | Profile | |
| Robert MD | Chief Officer | Profile | |
| John Moore | General Counsel | Profile | |
| Behrad Derakhshan | Chief Officer | Profile | |
| Marc MD | Chief Officer | Profile |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.